65,437 trials
Gastric, or Gastroesophageal Junction Adenocarcinoma
Primary: Overall Survival in PD-L1 Positive Participants — 17.2; 12.6 months — p=0.0056
Alzheimer's Disease · Cognitive Impairment · Tauopathies
Primary: Overview of Treatment-Emergent Adverse Events, Safety Set — 6; 17; 6; 8 Participants
Nonalcoholic Fatty Liver · Nonalcoholic Steatohepatitis · Fatty Liver
Primary: Mean Difference in Aspartate Transaminase (AST) Value in U/L Unit Between Pre-imaging and day7 Post-imaging — -0.5 international units per liter
Glioblastoma
Primary: To Measure the Reproducibility of qDCE-MRI Measurement of Glioblastoma. — 5 %COV
End Stage Renal Disease on Hemodialysis
Primary: Evaluation of the PK Profile of Difelikefalin - Cmax - Dose 1 — 3.70 ng/mL
Atopic Dermatitis
Primary: Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or…
Chronic Limb Threatening Ischemia
Primary: EuroQoL-5D Visual Acuity Scale (VAS) Score — 47.55; 69.15; 65.35 score on a scale — p=0.005
Fibromyalgia · Myofascial Pain Syndrome · Muscular Diseases
Primary: Functional Disability Inventory — 25.78; 24.10; 25.96; 21.83 score on a scale
Cataract
Primary: Binocular Distance Corrected Intermediate Visual Acuity at 66 cm Under Mesopic Conditions. — 0.27; 0.32 logMAR
Gastrointestinal Stromal Tumors
Primary: Part 1: Recommended Phase 2 Dose (RP2D) of CGT9486 — 1000 mg
Chorioretinal Vascular Disease
Primary: Percentage of IVT Injections Successfully Administered — 100; 100 Percentage of Successful Injections
Sickle Cell Disease · COVID-19
Primary: Antibody Response to COVID-19 Vaccine in Persons With Sickle Cell Disease — 32.155 units per mL
Substance Use
Primary: Enrollment and Recruitment Rate — 61; 62 Participants
Congenital Hearing Loss
Primary: Number of Participants Who do Not Receive Diagnostic Audiological Testing (Aim 1) — 378; 336 Participants
Overactive Bladder · Urinary Urge Incontinence · Overactive Bladder Syndrome
Primary: Change in Overactive Bladder Questionnaire Long Form Score (Symptoms Severity Sub-scale)(OAB-Q LF) — -31.2; -39.5 units on a scale